Prevalence and effect of bacterial co-infections on clinical outcomes in hospitalized **COVID-19** patients at a tertiary care centre of India Ashutosh Pathak¹, Sweta Singh¹, Sanjay Singh¹, Sangram Singh Patel¹, Nida Fatima¹, Atul Garg¹, Ujjala Ghoshal^{1*}, Chinmoy Sahu^{1*} Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India¹. *Corresponding authors Running title: Bacterial co-infections in COVID-19. Correspondence Dr. Chinmoy Sahu sahu.chinmoy@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 Abstract

Background: Bacterial co-infections are a leading cause of morbidity and mortality during viral infections including COVID-19. Systematic testing of COVID-19 patients having bacterial co-infections is essential to select the correct antibiotic for treatment in order to reduce mortality and also prevent spread of antimicrobial resistance (AMR). The present study aims to evaluate the prevalence, demographic parameters, antibiotic sensitivity patterns and outcomes in hospitalized COVID-19 patients with bacterial co-infections.

Methods: A total of 1019 COVID-19 patients were selected for the study. We analyzed the
 prevalence, antibiotic sensitivity pattern and clinical outcomes in COVID-19 patients having
 bacterial co-infections.

Results: Out of a total 1019 COVID-19 patients screened, 5.2% of patients demonstrated 36 clinical signs of bacterial co-infection. Bacteremia was found in majority of the patients 37 followed by respiratory and urinary infections. Escherichia coli, Pseudomonas aeruginosa 38 and Klebsiella spp. were most common isolates among the Gram-negative and Coagulase-39 negative Staphylococci (CONS) and Staphylococcus aureus among the Gram-positive 40 bacterial infections. Antibiotic sensitivity profiling revealed that colistin, imipenem and 41 fosfomycin were the most effective drugs against the Gram-negative isolates while 42 vancomycin, teicoplanin and doxycycline against the Gram-positive isolates. Analysis of 43 clinical outcomes revealed that the mortality rate was higher (39%) among the patients with 44 bacterial co-infections as compared to the group without co-infection (17%). 45

46 Conclusions: This study reveals that the rate of bacterial co-infections is significantly 47 increasing among COVID-19 patients and leading to increase in mortality. Systematic testing 48 of bacterial co-infections is therefore essential in COVID-19 patients for better clinical 49 outcomes and to reduce AMR.

50 Keywords: Bacterial co-infections, COVID-19, antimicrobial drug resistance.

51 Introduction

52 The human race has witnessed the emergence of four severe viral outbreaks in the last two decades: the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) epidemic in 53 54 2002, the influenza A H1N1 pandemic in 2012, Middle East Respiratory Syndrome (MERS) outbreak in 2009 and most recently the COVID-19 pandemic [1]. COVID-19 has emerged as 55 a global pandemic affecting millions of people world-wide and is proving to be a greater 56 57 danger than MERS and SARS Coronaviruses [2]. A plethora of symptoms have been described in the past few months, clearly indicating that COVID-19 is a complex disease, 58 59 which in no way consists only of a respiratory infection. It presents with a variety of unspecific symptoms so that the differential diagnosis encompasses a wide range of 60 infections.Most common symptoms of COVID-19 include respiratory symptoms like cough, 61 62 sputum, shortness of breath, fever; musculoskeletal symptoms like myalgia, joint pain, headache, fatigue; enteric symptoms like abdominal pain, vomiting, diarrhea and 63 mucocutaneous symptoms (less common) [3]. Lung infections may progress in a few cases to 64 ARDS (Acute respiratory distress syndrome), shock and death. Cytokine storm, immune 65 dysregulation and various viral evasion mechanisms in the presence of various co-morbid 66 conditions has contributed to fatal outcomes in the COVID-19 patients [4]. 67

Super-infection with bacterial pathogens has been identified in various viral respiratory 68 illnesses in the past and contributed to significant rates of morbidity and mortality [5-7]. 69 70 Mortality has been reported to be as high as 20-30% in such cases of super-infection [7, 8]. Existence of bacterial co-pathogens in such respiratory patients leads to increased hospital 71 stay, greater chances of acquiring nosocomial infections and overall increase in cost of 72 73 hospital stay [9]. SARS-CoV-2 is a new virus with still limited knowledge about its pathogenesis and clinical manifestations. Hence, there are several areas of knowledge gap 74 regarding this novel Coronavirus. One such area of potential research and studies is about the 75

co-existence, prevalence and incidence of bacterial pathogens in SARS-CoV-2[10, 11].
Various anti-viral and immuno-modulatory agents are being tried in COVID-19 hospitalized
patients, and several others are in experimental phase and under trials. Antibiotics are of no
use in such patients but are routinely prescribed due to the potential risk of secondary
bacterial infections [10]. Various studies have advocated the use of antibiotics in patients
suffering from respiratory symptoms of COVID-19 [12, 13]. However, such irrational and
unguided antibiotic use ultimately leads to emergence of antimicrobial resistance [11].

Hence, there is a dire need to study bacterial co-infections in COVID-19 patients and understand the exact prevalence of such co-pathogens for the proper and rational use of antibiotics. This study was planned with the aim to study the prevalence, demographic parameters, risk factors, antibiotic sensitivity patterns and outcomes in hospitalized COVID-19 patients with bacterial co-infections.

88 Material and Methods

89 Place & Duration of Study

90 The study was conducted at a tertiary care hospital of Northern India from March 2020 to
91 August 2020 (six months) during the COVID-19 pandemic.

92 Study design

During the time span of six months; a total of 1019 hospitalized COVID-19 patients were included in the study. The patients were analyzed for the presence of bacterial co-infection as determined by the presence of characteristic clinical features and culture positive blood, respiratory, urine or pus/aspiration samples. The patients who were confirmed to have bacterial co-infection were further analyzed. We collected following information on COVID-19 patients with bacterial co-infection: demographic details of the admitted patients, presence of co-morbidities (if any), date of admission and culture-positive results, day of

hospitalization on which bacterial culture was sent, antibiotic susceptibility profiles of thebacterial isolates, length of hospital stay and clinical outcomes in the patients.

102 Molecular testing for SARS CoV-2

Two swabs, one oropharyngeal and the other deep nasal swab were collected from the patients suspected of having SARS CoV-2and transported in viral transport media (VTM) to the laboratory. Viral RNA extraction was done using the QIAampViral RNA kit (Qiagen Inc., USA) according to the manufacturer's instructions. Real Time PCR was performed by Applied Biosystems TaqPath COVID-19 kit (Thermo Fisher Scientific, USA) according to the manufacturer's instructions.

109 Bacterial culture & processing

All the specimens (blood, respiratory, urine or pus /aspiration) were cultured on both MacConkey and blood agar plates according to standard microbiological techniques. Further, colonies were isolated and subcultures done accordingly. The bacterial isolates were first identified using routine staining and biochemical tests [14]. The identities of bacteria were further confirmed by MALDI-TOF MS and Vitek 2 system (Biomerieux Inc., France), an automated identification and susceptibility testing system[15].

116 Antibiotic susceptibility testing

Antibiotic susceptibility testing was done by Kirby-Bauer's disk diffusion method on Muller
Hinton agar [16]. Results were interpreted based on Clinical and Laboratory Standards
Institute (CLSI) guidelines [17].

120 Patient follow-up

Organism profiles, sensitivity and other study parameters were kept in computer database along with particulars of the patients. WHO classified the drug usage in hospitalized patients as per the AWaRe criteria : Access, Watch and Reserve .This criteria was used to study the overall trend

of antibiotic usage in the patients. Follow up was planned in the suspected cases for any repeatculture, outcomes & associated co-morbidities.

126 Statistical Analysis

127 The results were analyzed using the SPSS version 22 software (SPSS Inc., Chicago, IL, 128 USA). The frequencies are shown with 95% confidence intervals (95% CI). The Chi-square 129 and Mann-Whitney U test was used to analyse the statistically significant variables. The 130 statistically significant values were considered as p-value<0.05.</p>

131

132 **Results**

A total of 1019 patients tested positive for COVID-19 in a span of six months and were 133 hospitalized at our COVID hospital. Out of these hospitalized COVID-19 patients, 5.2% 134 (n=53/1019) showed clinical signs of bacterial co-infection. Out of the total number of 135 patients having confirmed diagnosis of bacterial co-infection, a majority (66%; n=35/53) 136 acquired infections in the hospital (>48 hours of admission). The mean age of the patients 137 was 68 years (SD=57 + 16) and it ranged from 8-75 years. Males comprised the majority of 138 the cases (61 %; n=32/53) as compared to females. Various co-morbidities in the patients 139 were also studied; hypertension (61%; n=32/53) and diabetes mellitus (58%; n=31/53) 140 emerged as the most prevalent medical conditions. COPD/Asthma (27%; n=14/53), chronic 141 kidney disease (CKD) (23%; n=12/53) and chronic liver diseases (CLD) (19%; n=10/53) 142 were the other major co-morbidities among the COVID-19 patients. 143

144 Etiology of the bacterial co-infections

Among the various samples collected from COVID-19 patients suffering from co-infections, blood was received from majority of the cases (37%; n=20/53). Urine (31%; n=16/53), respiratory specimens (28%; n=14/53) and pus/aspirated fluid (4%; n=3/53) contributed for

the other bacteriological samples. Bacteremia was seen in majority of the COVID-19 positivepatients; followed by respiratory and urinary symptoms.

150 E. coli was the common isolate (21%; n=11/53), followed by Pseudomonas aeruginosa (13.2%; n=7/53) and *Klebsiella spp.* (11.3%; n=6/53) among the Gram-negative organisms. 151 Burkholderia cepacia, Stenotrophomonas maltophila, Morganella morganii and Proteus 152 mirabilis were isolated from one patient each. On the other hand; Coagulase-negative 153 154 Staphylococci (CONS) (18.8 %; n=10/53) and Staphylococcus aureus (17%; n=9/53) formed the majority of isolates in Gram-positive organisms. Methicillin resistant Staphylococcus 155 156 aureus (MRSA) was seen in 4, Methicillin resistant coagulase-negative Staphylococci (MRCONS) in 7, Enterococcus spp. in 5 and Streptococcus spp. in 1 case. 157

158 Antibiotic sensitivity profile of bacterial isolates

Antibiotic sensitivity testing revealed colistin (99%), imipenem (78%) and fosfomycin (95%) (only in urinary isolates) as the most effective drugs against Gram-negative isolates whereas vancomycin (100%), teicoplanin (99%) and doxycycline (71%) emerged as the most potent drugs for Gram-positive bacterial infections. Detailed antibiotic sensitivity patterns for both Gram-negative and Gram-positive isolates are summarized in Fig 1 & 2 respectively.

164 Antibiotic usage

As per the WHO criteria of AWaRe class of antibiotics, maximum antibiotics were prescribed from

the "watch" (48.02 %) and "reserve" categories (24.21 %). Only 20.7 % were given antibiotics from

the "access" category while 7.07 % of the patients were not recommended any antibiotics as depictedin Fig 3 A & B.

169 Clinical Outcomes

The two groups of COVID-19 positive patients with and without bacterial co-infections were compared in different clinical parameters and outcomes (Table 1). Patients with bacterial coinfections belonged to the older age group as compared to the patients without bacterial coinfections. No statistical significance was noted in terms of gender and other co-morbidities

like hypertension, diabetes, CKD, CLD, COPD/asthma on comparing between the two 174 groups. However; on comparing the clinical outcomes a significant difference was noted in 175 terms of in-patient mortality, number of patients requiring intubation, use of ventilators and 176 vasopressors. Patients with bacterial co-infections experienced a mortality rate of 39% as 177 compared to non-co-infection group (17%). The requirement of ventilators was higher in 178 patients with co-infection (35%) as compared to the non-co-infection group (21%). 179 180 Similarly, a higher percentage of patients with bacterial co-infections (37%) needed intubation as compared to non-co-infection group (29%). Requirement of vasopressive drugs 181 182 was more in patients with bacterial co-infections (32%) as compared to the patients with coinfection (14%). 183

184 **Discussion**

SARS CoV-2 is a newly emerging virus which has led to a global pandemic in a span of only 185 a few months. Its immunology, pathogenesis, clinical features and implications on the health 186 care settings are yet to be fully understood. There is a lack of clinical research and data on the 187 bacterial infections in these COVID-19 patients. Our study reported a bacterial co-infection 188 rate of 5.2 % which is very well in agreement to other similar studies done in various parts of 189 the world. A case series from Washington reported bacterial co-infection rate as 4.8%; while 190 some studies from China also reported a rate of 5-9% [18-24]. A meta-analysis done by 191 192 Lansbury et al., reported a bacterial co-infection rate of around 6.8% in hospitalized COVID-193 19 cases [25].

The current study stressed the prevalence of bacterial co-infections to be higher among the elderly age group (>65years). Several studies have emphasized the point of enhanced pathogenesis of COVID-19 in the elderly age group. A lot of factors like decreased mucociliary clearance, ciliary ultrastructural anomalies and immunosenescence play a key role in this. "Inflamm-aeging "or increased release of inflammatory mediators and cytokines

leading to a cytokine surge is involved in tissue damage and multi-organ failure in such 199 patients [26]. A higher proportion of co-morbidities like diabetes and hypertension were seen 200 in the COVID cases in our study. This can be supported by the fact that diabetes mellitus 201 itself down-regulates the immune system by decreasing the effective T-cell and neutrophils 202 response [27]. It causes decreased phagocytosis, ineffective chemotaxis and decreased killing 203 of invading microbes by neutrophils and macrophages leading to increased susceptibility to 204 205 secondary bacterial infection [28]. Our study however failed to show any statistical significance for the association of various co-morbidities to the increase in bacterial co-206 207 infection rates among the COVID-19 cases. As such no role of increase in bacterial coinfection rates per se have been described so far in this sub-group of patients. 208

Extensive search of literature revealed that there is no available report of high rate of 209 210 bacteremia and concurrent urinary tract infection (UTI) in COVID-19 patients. Ours is first 211 such study revealing bacteremia (37%) and UTIs (31%) as the most common co-infections in COVID-19 patients. Other isolates were also isolated from respiratory (28%) and pus/aspirate 212 (4%) samples in the current study. E. coli, Klebsiella and Pseudomonas were the predominant 213 Gram-negative pathogens. One similar study in COVID-19 patients reported UTI in almost 214 half of the patients (57%) [29]. It also reported E. coli and Enterobacter cloacae as the most 215 commonly isolated pathogens. Another study by Lansbury et al., reported respiratory 216 pathogens such as Mycoplasma pneumoniae, P. aeruginosa, and Haemophilus influenza as 217 218 the most common isolates [25]. Increased prevalence of Gram-negative as well as Grampositive pathogens in the current study can be attributed to the immune dysregulation leading 219 to nosocomial infections and gut dysbiosis in COVID-19 positive patients. The inflammatory 220 221 mediators disrupt the intestinal permeability leading to the leakage of gut microbes and associated metabolites into circulation. The leaked microbes and products via circulation 222 migrate to organs including lungs and produce bacteremia, UTIs and various other infections 223

[30]. Higher rates of diabetes in our group of patients also predispose to increase in secondary
bacterial infections including UTIs [31]. Immune dysregulation in SARS-CoV-2 infection is
characterized by lymphopenia, increased neutrophil–lymphocyte ratio, decreased NK-cells
and CD8+T-cell activity, decreased regulatory T-cells and increased CD4+ to CD8+ ratio.
Failure to eliminate virus due to inappropriate IFN response and decreased number and
function of CD8+ and NK-cells further leads to virus induced tissue damage and makes the
body more prone to secondary bacterial infections [31].

Colistin, Fosfomycin and Vancomycin proved to be some very effective drugs in treating 231 232 bacterial infections in COVID-19 positive cases. Administration of antibiotics in this coinfection sub-group is vital to combat the ongoing bacterial infection in the form of blood 233 stream, urinary and respiratory infections as well as to avoid the increased chances of 234 acquiring secondary bacterial infections in such co-morbid patients. There was no significant 235 236 past history of any antibiotic or antimicrobial usage in these groups of patients. Providing the correct and narrowed antibiotic coverage through proper antibiotic sensitivity testing will 237 look after the ill effects caused by broader empiric treatment in such cases. As already 238 highlighted in the study, most antibiotics prescribed were from the "watch" and "reserve" 239 categories of WHO AWaRe classification. Antibiotic stewardship programmes will lead the 240 path towards righteous treatment in COVID-19 infection group and will prevent the after 241 effects of long term treatment. 242

Discussing the clinical outcomes of our study, we noticed a much higher rate of in-patient mortality in bacterial co-infection COVID-19 group (39%) as compared to the no infection group (17%). A similar study by Alvaro et al., reported a mortality rate of 50% in COVID-19 patients with concomitant bacterial infection [29]. While a study from Wuhan, China also reported similar mortality rates in this group of patients [20]. The increase in mortality rates may also be attributed to the older population involved with bacterial co-infections along

with presence of other co-morbidities [32, 33]. The older population has weakened immune 249 system due to immunosenescence and hence succumbs to the infections more easily than the 250 younger ones. These people, therefore, more likely require interventions in the form of 251 intubation, mechanical ventilation and use of vasopressive drugs to improve the outcome and 252 increase their life expectancy. This fact was strongly suggested by our study where we 253 noticed statistical significance in these COVID-19 cases with bacterial co-infection for the 254 255 use of ventilator support, intubation and use of vasopressors as compared to the no infection 256 group.

A lot of aspects still need to be explored in the current COVID-19 pandemic situation for the better understanding of its pathogenesis and control. Bacterial co-infections not necessarily but certainly may increase the mortality rates in COVID-19 positive patients. Antibiotic prescription as well as usage in this current situation must be properly guided through proper culture reports, sensitivity testing and stringent antibiotic stewardship programmes.

262 **Declarations**

263 **Funding:** None

Conflicts of interest/Competing Interests: The authors declare that they have no conflict of
 interest/competing interests.

Ethics approval: The study was approved by the institutional ethics committee of Sanjay
Gandhi Post Graduate Institute of Medical Sciences under reference number 2020-100-EMPEXP-16. Since, the study does not involve direct participation of human subjects so waiver of
consent was granted.

270 **Consent to participate:** Not applicable

Availability of data and material: The datasets used and/or analyzed during the currentstudy are available from the corresponding author on reasonable request.

273	Author's contributions: AP and CS conceptualized and supervised the study. AP, SS, SS
274	and NF collected the samples, performed the testing and drafted the manuscript. AG, UG,
275	SSP, AP and SS supervised the COVID-19 testing. AP and CS edited the manuscript.
276	

277 **REFERENCES**

- Guarner J. Three Emerging Coronaviruses in Two Decades. Am J Clin Pathol.
 2020;153(4):420-1.
- 280 2. Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus

281 2019) - recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006-11.

- 282 3. World Health Organization. Transmission of SARS-CoV-2: Implications for infection
- 283 prevention precautions. https://www.who.int/publications/i/item/modes-of-transmission-
- 284 of-virus-causing-COVID-19-implications-for-ipc-precaution-recommendations
- 285 (Accessed on September 10, 2020).
- 4. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of
 COVID-19. J Pharm Anal. 2020;10(2):102-8.
- 288 5. Esper FP, Spahlinger T, Zhou L. Rate and influence of respiratory virus co-infection on
 289 pandemic (H1N1) influenza disease. J Infect. 2011;63(4):260-6.
- Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, et al. The frequency of
 influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza
 Other Respir Viruses. 2016;10(5):394-403.
- 293 7. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, 3rd, et al. Critical
- illness from 2009 pandemic influenza A virus and bacterial coinfection in the United
- 295 States. Crit Care Med. 2012;40(5):1487-98.

- Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell Jt, Mangino JE, et al.
 Bacterial and viral co-infections complicating severe influenza: Incidence and impact
 among 507 U.S. patients, 2013-14. J Clin Virol. 2016;80:12-9.
- 9. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C,
- et al. Community-acquired respiratory coinfection in critically ill patients with pandemic
- 301 2009 influenza A(H1N1) virus. Chest. 2011;139(3):555-62.
- 10. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect
 antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808-10.
- 11. Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and
 unexplored in COVID-19. Lancet Microbe. 2020;1(1):e11.
- 306 12. Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. Clin Microbiol Infect.
 307 2020. https://doi: 10.1016/j.cmi.2020.09.055.
- 308 13. Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al.
 309 Recommendations for antibacterial therapy in adults with COVID-19 an evidence
 310 based guideline. Clin Microbiol Infect. 2021;27(1):61-6.
- 14. Collee JG, Miles RS, Watt B.Tests for identification of bacteria In: Collee JG, Fraser
- AG, Marmion BP, Simmons A (eds): Mackie and McCartney Practical Medical
 Microbiology, 14th ed, NewYork: Churchill –Livingstone, pp 131-50.1996.
- Ling TK, Tam PC, Liu ZK, Cheng AF. Evaluation of VITEK 2 rapid identification and
 susceptibility testing system against gram-negative clinical isolates. J Clin Microbiol.
 2001:39(8):2964-6.
- 16. Jan Hudzicki. 2009. Kirby-bauer disk diffusion susceptibility test protocol.
- 318 17. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial
 319 Susceptibility Testing. CLSI supplement M100S. 27th ed. Wayne, PA: Clinical and
 320 Laboratory Standards Institute; 2017.

- 18. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics
- and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. Jama.
 2020;323(16):1612-4.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of
 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
 retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81.
- 20. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With
 Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769-77.
- 329 21. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of
 330 refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020. https://doi:
 331 10.1093/cid/ciaa270.
- 332 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
 333 infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497334 506.
- 23. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
 descriptive study. Lancet. 2020;395(10223):507-13.
- 24. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities:
 A Multicenter Study of Clinical Features. Am J Respir Crit Care Med.
 2020;201(11):1380-8.
- 25. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a
 systematic review and meta-analysis. J Infect. 2020;81(2):266-75.
- 26. Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D'Agnano V, et al. COVID-19 and
 the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res.
 2020;32(8):1599-608.

- 27. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review
- of pathogenesis. Indian J Endocrinol Metab. 2012;16 Suppl 1(Suppl1):S27-36.
- 28. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two
 epidemics. Lancet Infect Dis. 2009;9(12):737-46.
- 29. Goncalves Mendes Neto A, Lo KB, Wattoo A, Salacup G, Pelayo J, DeJoy R, 3rd, et al.
 Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med
- 352 Virol. 2020. https:// doi: 10.1002/jmv.26441.
- 353 30. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity,
- inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-74.
- 355 31. de Lucena TMC, da Silva Santos AF, de Lima BR, de Albuquerque Borborema ME, de
- Azevedo Silva J. Mechanism of inflammatory response in associated comorbidities in
 COVID-19. Diabetes Metab Syndr. 2020;14(4):597-600.
- 358 32. Ambite I, Nagy K, Godaly G, Puthia M, Wullt B, Svanborg C. Susceptibility to Urinary
 359 Tract Infection: Benefits and Hazards of the Antibacterial Host Response. Microbiol
 360 Spectr. 2016;4(3).
- 361 33. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism
 362 of cytokine storm in elderly adults with COVID-19 infection: the contribution of
 363 "inflame-aging". Inflamm Res. 2020;69(9):825-39.
- 364

365

- 366 367
- 368
- 369

370

570

371

- Table 1: Comparison of co-morbidities and clinical outcomes in the two groups of COVID-
- 373 19 patients (with and without bacterial co-infections).

Clinical parameters	Cases with bacterial	Cases without	P-values
	co-infection (n =	bacterial co-	
	53, %)	infection (n=966,	
		%)	
Age (Mean ,Range in	68 (8 - 75)	59 (3-71)	0.007
years)			
Gender			
Males	32 (61)	609 (63)	0.019
Females	21 (39)	357 (37)	
<u>Co-morbidities</u>			
Hypertension	32(61)	628(65)	0.622
Diabetes Mellitus	31(58)	608(63)	0.588
COPD/Asthma	14(27)	280(29)	0.712
CKD	12(23)	174(18)	0.421
CLD	10(19)	203(21)	0.399
Heart diseases	5(10)	125(13)	0.512
Malignancies	7(14)	87 (9)	0.098
(Organ/Hematological)			
<u>Outcomes</u>			
In-patient mortality	21(39)	164(17)	< 0.001
Use of Ventilators	18(35)	203(21)	< 0.001
Use of vasopressive drugs	17(32)	135(14)	< 0.001
Intubation	19(37)	251(29)	0.120







Fig 1: Antibiotic sensitivity pattern in Gram-negative isolates.







386

Fig 2: Antibiotic sensitivity pattern in Gram-positive isolates.

388

389





393 classification. (A) Total antibiotics usage in %. (B) Class of antibiotics usage in %.